phenylacetylglutamine has been researched along with Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Figg, WD | 1 |
| Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM | 1 |
| Adamson, P; Aiken, A; Balis, F; Berg, S; Blaney, SM; Jakacki, R; Klenke, R; Murry, DJ; Packer, R; Serabe, BM; Thompson, P | 1 |
| NEISH, WJ | 1 |
| Figg, WD; Headlee, D; Lieberman, R; Myers, CE; Piscitelli, SC; Samid, D; Thibault, A; Tompkins, A | 1 |
| Baker, SD; Bowling, MK; Carducci, MA; Donehower, RC; Figg, WD; Gilbert, J; Grochow, L; Zabelina, Y | 1 |
| Bowling, MK; Carducci, MA; Chen, TL; Donehower, RC; Eisenberger, MA; Gilbert, J; Grochow, LB; Noe, D; Sinibaldi, V; Zabelina, Y | 1 |
4 trial(s) available for phenylacetylglutamine and Neoplasms
| Article | Year |
|---|---|
Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.
Topics: Adolescent; Adult; Antineoplastic Agents; Biotransformation; Child; Child, Preschool; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Female; Glutamine; Half-Life; Humans; Infant; Infusions, Intravenous; Male; Models, Biological; Neoplasms; Phenylacetates; Spectrophotometry, Ultraviolet | 2003 |
Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine.
Topics: Adult; Aged; Female; Glutamine; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Phenylacetates; Phenylbutyrates | 1995 |
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Edema; Fatigue; Female; Glutamine; Humans; Hypocalcemia; Male; Middle Aged; Nausea; Neoplasms; Nervous System Diseases; Phenylacetates; Phenylbutyrates; Treatment Outcome; Vomiting | 2001 |
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
Topics: Adult; Antineoplastic Agents; Chromatography, High Pressure Liquid; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Fatigue; Female; Glutamine; Humans; Hypokalemia; Infusions, Intravenous; Male; Metabolic Clearance Rate; Nausea; Neoplasms; Neutropenia; Patient Dropouts; Phenylacetates; Phenylbutyrates; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Tumor Cells, Cultured; Uric Acid | 2001 |
3 other study(ies) available for phenylacetylglutamine and Neoplasms
| Article | Year |
|---|---|
Antineoplastons: when is enough enough?
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Evidence-Based Medicine; Glutamine; Humans; Neoplasms; Neurotoxicity Syndromes; Patient Safety; Phenylacetates; Quackery; Risk Assessment; Treatment Outcome | 2018 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalopathy; Humans; Liver; Neoplasms; Phenylacetates; Phenylbutyrates; Randomized Controlled Trials as Topic; Urea Cycle Disorders, Inborn | 2013 |
Specific rotation of phenylacetylglutamine excreted by cancer patients and normal subjects.
Topics: Encephalomyelitis; Glutamine; Neoplasms; Rotation | 1958 |